206 related articles for article (PubMed ID: 23612969)
1. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.
Odell AF; Odell LR; Askham JM; Alogheli H; Ponnambalam S; Hollstein M
J Biol Chem; 2013 Jun; 288(23):16704-16714. PubMed ID: 23612969
[TBL] [Abstract][Full Text] [Related]
2. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
4. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
Aydin S; Ambroise J; Cosyns JP; Gala JL
Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
[TBL] [Abstract][Full Text] [Related]
6. Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform.
Wei QX; Odell AF; van der Hoeven F; Hollstein M
Cell Cycle; 2011 Apr; 10(8):1261-70. PubMed ID: 21445009
[TBL] [Abstract][Full Text] [Related]
7. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
Boot A; Jiang N; Rozen SG
Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
[TBL] [Abstract][Full Text] [Related]
8. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.
Xiao J; Zhu X; Hao GY; Zhu YC; Hou HJ; Zhang J; Ma LL; Tian Y; Zhang YH
Transplant Proc; 2011 Dec; 43(10):3751-4. PubMed ID: 22172840
[TBL] [Abstract][Full Text] [Related]
9. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
10. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
[TBL] [Abstract][Full Text] [Related]
12. p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.
Slade N; Moll UM; Brdar B; Zorić A; Jelaković B
Mutat Res; 2009 Apr; 663(1-2):1-6. PubMed ID: 19428366
[TBL] [Abstract][Full Text] [Related]
13. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
14. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.
Kucab JE; Phillips DH; Arlt VM
FEBS J; 2010 Jun; 277(12):2567-83. PubMed ID: 20553493
[TBL] [Abstract][Full Text] [Related]
15. Mutation spectra of Kras and Tp53 in urethral and lung neoplasms in B6C3F1 mice treated with 3,3',4,4'-tetrachloroazobenzene.
Bhusari S; Malarkey DE; Hong HH; Wang Y; Masinde T; Nolan M; Hooth MJ; Lea IA; Vasconcelos D; Sills RC; Hoenerhoff MJ
Toxicol Pathol; 2014; 42(3):555-64. PubMed ID: 23703846
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
18. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene.
Liu Z; Hergenhahn M; Schmeiser HH; Wogan GN; Hong A; Hollstein M
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):2963-8. PubMed ID: 14976251
[TBL] [Abstract][Full Text] [Related]
19. Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.
Aydin S; Dekairelle AF; Ambroise J; Durant JF; Heusterspreute M; Guiot Y; Cosyns JP; Gala JL
PLoS One; 2014; 9(9):e106301. PubMed ID: 25184754
[TBL] [Abstract][Full Text] [Related]
20. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]